High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening

References

• Ho M. Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin. BioDrugs 2011; 25:275 - 84; http://dx.doi.org/10.2165/11595360-000000000-00000; PMID: 21942912
   PubMed Web of Science ®Google Scholar
• Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125:89 - 97; http://dx.doi.org/10.1016/S0016-5085(03)00689-9; PMID: 12851874
   PubMed Web of Science ®Google Scholar
• Capurro M, Filmus J. Glypican-3 as a serum marker for hepatocellular carcinoma. Cancer Res 2005; 65:372 - , author reply 372-3; PMID: 15665316
   PubMed Web of Science ®Google Scholar
• Ho M, Kim H. Glypican-3: a new target for cancer immunotherapy. Eur J Cancer 2011; 47:333 - 8; http://dx.doi.org/10.1016/j.ejca.2010.10.024; PMID: 21112773
   PubMed Web of Science ®Google Scholar
• Allegretta M, Filmus J. Therapeutic potential of targeting glypican-3 in hepatocellular carcinoma. Anticancer Agents Med Chem 2011; 11:543 - 8; PMID: 21554204
   PubMed Web of Science ®Google Scholar
• Ishiguro T, Sugimoto M, Kinoshita Y, Miyazaki Y, Nakano K, Tsunoda H, et al. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res 2008; 68:9832 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-08-1973; PMID: 19047163
   PubMed Web of Science ®Google Scholar
• Nakano K, Orita T, Nezu J, Yoshino T, Ohizumi I, Sugimoto M, et al. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem Biophys Res Commun 2009; 378:279 - 84; http://dx.doi.org/10.1016/j.bbrc.2008.11.033; PMID: 19022220
   PubMed Web of Science ®Google Scholar
• Nakano K, Ishiguro T, Konishi H, Tanaka M, Sugimoto M, Sugo I, et al. Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization. Anticancer Drugs 2010; 21:907 - 16; http://dx.doi.org/10.1097/CAD.0b013e32833f5d68; PMID: 20847643
   PubMed Web of Science ®Google Scholar
• Nakatsura T, Komori H, Kubo T, Yoshitake Y, Senju S, Katagiri T, et al. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res 2004; 10:8630 - 40; http://dx.doi.org/10.1158/1078-0432.CCR-04-1177; PMID: 15623647
   PubMed Web of Science ®Google Scholar
• Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, et al. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 2006; 12:2689 - 97; http://dx.doi.org/10.1158/1078-0432.CCR-05-2267; PMID: 16675560
   PubMed Web of Science ®Google Scholar
• Suzuki S, Yoshikawa T, Hirosawa T, Shibata K, Kikkawa F, Akatsuka Y, et al. Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma. Cancer Sci 2011; 102:1622 - 9; http://dx.doi.org/10.1111/j.1349-7006.2011.02003.x; PMID: 21668581
   PubMed Web of Science ®Google Scholar
• Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, Ihara S, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004; 64:2418 - 23; http://dx.doi.org/10.1158/0008-5472.CAN-03-2191; PMID: 15059894
   PubMed Web of Science ®Google Scholar
• Yu L, Feng M, Kim H, Phung Y, Kleiner DE, Gores GJ, et al. Mesothelin as a potential therapeutic target in human cholangiocarcinoma. J Cancer 2010; 1:141 - 9; http://dx.doi.org/10.7150/jca.1.141; PMID: 20922056
   PubMed Web of Science ®Google Scholar
• Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495 - 7; http://dx.doi.org/10.1038/256495a0; PMID: 1172191
   PubMed Web of Science ®Google Scholar
• Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol 2012; 22:3 - 13; http://dx.doi.org/10.1016/j.semcancer.2011.12.009; PMID: 22245472
   PubMed Web of Science ®Google Scholar
• Chiarella P, Fazio VM. Mouse monoclonal antibodies in biological research: strategies for high-throughput production. Biotechnol Lett 2008; 30:1303 - 10; http://dx.doi.org/10.1007/s10529-008-9706-5; PMID: 18418716
   PubMed Web of Science ®Google Scholar
• Yokoyama WM, Christensen M, Santos GD, Miller D. Production of monoclonal antibodies. Curr Protoc Immunol 2006; Chapter 2:2 - , 5; PMID: 18432969
   PubMedGoogle Scholar
• Getts DR, Getts MT, McCarthy DP, Chastain EM, Miller SD. Have we overestimated the benefit of human(ized) antibodies?. MAbs 2010; 2:682 - 94; http://dx.doi.org/10.4161/mabs.2.6.13601; PMID: 20935511
   PubMed Web of Science ®Google Scholar
• Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006; 6:559 - 65; http://dx.doi.org/10.1038/nrc1891; PMID: 16794638
   PubMed Web of Science ®Google Scholar
• Harlow E, Lane D. Antibodies: a laboratory manual, Cold Spring Harbor, NY; Cold Spring Harbor Laboratory, 1988.
   Google Scholar
• Ho M, Kreitman RJ, Onda M, Pastan I. In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J Biol Chem 2005; 280:607 - 17; PMID: 15491997
   PubMed Web of Science ®Google Scholar
• Feng M, Kim H, Phung Y, Ho M. Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro. Int J Cancer 2011; 128:2246 - 7; http://dx.doi.org/10.1002/ijc.25549; PMID: 20617511
   PubMed Web of Science ®Google Scholar
• Man YG, Tavassoli FA. A simple epitope retrieval method without the use of microwave oven or enzyme digestion. Appl Immunohistochem 1996; 4:139 - 41
   Google Scholar